Director of Investor Relations & Corporate Development

Description

Precision Neuroscience is pioneering a brain implant, known as a brain-computer interface (BCI), to restore communication and independence for people with neurological conditions. Our cutting-edge technology is designed to empower people with paralysis to control digital devices—such as computers and smartphones—with their thoughts alone, opening new possibilities for daily life.

Precision’s multidisciplinary team brings together leading experts in diverse fields such as neurosurgery, artificial intelligence, machine learning, microfabrication, electrical engineering, and more. We are committed to turning breakthrough scientific advancements into real-world solutions for people affected by conditions such as spinal cord injury, stroke, and ALS.

As a Precision employee, you will be joining one of the fastest moving and best-capitalized companies in the emerging field of BCI. Since our founding in 2021, Precision has secured over $155 million in funding, developed and validated our technology, and initiated human trials in collaboration with some of the nation’s top hospitals.

We are seeking a dynamic and experienced Director of Investor Relations and Corporate Development to manage investor relations and help shape Precision Neuroscience’s corporate strategy.

This role will lead our investor relations strategy and execution and will be a key contributor to our corporate strategy. This is a unique opportunity to be part of shaping the strategy for a distributive new category in medical technology.

This position is on-site at our Manhattan office. To be eligible for this role you must currently be based in the United States, and have working rights.

Key Responsibilities

Key Responsibilities

• Develop and execute investor relations strategy aligned with the company’s corporate goals and enhancing its reputation within the financial community.
• Craft and maintain a compelling and consistent investment narrative; serve as a key contributor to the company’s external messaging.
• Serve as a primary point of contact for the investment community, fostering strong relationships with current and potential investors.
• Plan, coordinate, and participate in investor outreach, meetings, diligence responses and other investor activities.
• Conduct in-depth market analysis, competitive intelligence, and landscape assessments to identify key industry trends, risks, and opportunities in the BCI and neurotechnology sectors.
• Identify and evaluate new growth opportunities, including potential M&A, strategic partnerships, joint ventures, and new market entry.
• Develop comprehensive business cases and financial models for strategic initiatives to support executive and board-level decision-making.

Skills, Knowledge and Expertise

Bachelor’s degree in Finance, Economics, Life Sciences, or a related field. An MBA or other advanced degree (PhD, MD) is strongly preferred.

Diverse workforces create the best culture, company, and products. We at Precision are committed to an inclusive culture that celebrates the uniqueness and contributions of everyone.  As an equal opportunity employer, Precision does not discriminate on the basis of sex, race, religion, national origin, disability status, protected veteran status, or any other characteristic protected by law.

Precision Neuroscience is pioneering a brain implant, known as a brain-computer interface (BCI), to restore communication and independence for people with neurological conditions. Our cutting-edge technology is designed to empower people with paralysis to control digital devices—such as computers and smartphones—with their thoughts alone, opening new possibilities for daily life.

Precision’s multidisciplinary team brings together leading experts in diverse fields such as neurosurgery, artificial intelligence, machine learning, microfabrication, electrical engineering, and more. We are committed to turning breakthrough scientific advancements into real-world solutions for people affected by conditions such as spinal cord injury, stroke, and ALS.

As a Precision employee, you will be joining one of the fastest moving and best-capitalized companies in the emerging field of BCI. Since our founding in 2021, Precision has secured over $155 million in funding, developed and validated our technology, and initiated human trials in collaboration with some of the nation’s top hospitals.